ZIMMER BIOMET HOLDINGS, INC. 4
4 · ZIMMER BIOMET HOLDINGS, INC. · Filed Feb 6, 2017
Insider Transaction Report
Form 4
DVORAK DAVID C
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2017-02-02−52,500→ 0 totalExercise: $83.68Exp: 2017-02-05→ Common Stock (52,500 underlying) - Exercise/Conversion
Common Stock
2017-02-02$83.68/sh+52,500$4,393,200→ 313,355 total - Sale
Common Stock
2017-02-02$117.77/sh−43,207$5,088,562→ 270,148 total
Footnotes (5)
- [F1]Securities acquired pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016.
- [F2]Includes 269 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan between May 2, 2016 and January 30, 2017.
- [F3]Securities sold to cover option exercise cost, taxes and fess pursuant to a written plan intended to comply with Rule 10b5-1(c)(1) adopted by Mr. Dvorak on September 14, 2016.
- [F4]Represents the sale of 43,207 shares in multiple transactions, ranging in price from $117.26 to $118.23 per share, resulting in a weighted average sale price of $117.7717. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- [F5]Vested annually over four years in increments of 25% each year, commencing on February 6, 2008.